Ergoteles’s Bionano Genomics BNGO Stock Holding History

Ergoteles’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-493	Closed	-$180K	–	139
2023 Q2	$180K	Buy	+493	New	+$223K	0.01%	864

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles's BNGO Position: Q3 2023 in Review

Ergoteles sold out of Bionano Genomics (BNGO) in Q3 2023, closing a stake of 493 shares — an estimated $180K sold.

Ergoteles first reported a position in BNGO in Q2 2023 and held it in 1 quarter. The position peaked at $180K in Q2 2023. 46 funds tracked by Wall St. Rank hold BNGO as of Q3 2023.

Ergoteles reported no remaining Bionano Genomics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 493 Bionano Genomics shares in Q3 2023, an estimated $180K.
Ergoteles first reported a position in Bionano Genomics in Q2 2023 and held it in 1 quarter.
Ergoteles's Bionano Genomics position peaked at $180K in Q2 2023.
46 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.